News

LHV Group's Strategic Share Acquisition During November 2025

LHV Group's Strategic Share Acquisition During November 2025

LHV Group's Strategic Share Acquisition Activities

LHV Group has made significant strides as it engages in share acquisition on the Nasdaq Tallinn Stock Exchange. From 14th to 20th November, the company actively acquired its own shares, demonstrating a proactive approach towards solidifying its market position.

Details of Share Acquisition

The recent share acquisitions are a reflection of LHV Group's commitment to enhancing shareholder value. For instance, on the 14th of November, LHV Group acquired 13,800 shares at a weighted average price of €3.26. This investment not only indicates the company's confidence in its growth trajectory but also aligns with its strategic objectives.

Acquisition Summary

Following this purchase, on the 17th of November, the company acquired an additional 1,527 shares at a slightly lower average price of €3.255. These transactions underscore a systematic approach toward managing shareholding and reinforcing investor confidence.

Authority and Compliance

The acquisitions were conducted under the guidelines established in the general meeting of shareholders, held earlier in the year. LHV Group remains fully compliant with the conditions set by its Supervisory Board, positioning itself favorably within the regulatory landscape.

Key Regulatory Information

Post-acquisition, LHV Group ensures that summary data is disclosed no later than seven trading days after the transactions. This transparency is vital for stakeholders and demonstrates the company's accountability to both investors and regulatory authorities.

About LHV Group

LHV Group stands as the largest domestic financial entity in Estonia, embodying a dynamic force in financial services. It’s significant to note that as of late October, LHV Pank serves over 486,000 clients, while its pension funds cater to more than 107,000 active participants. In addition, LHV Kindlustus provides coverage for approximately 229,000 individuals.

Broadening Financial Horizons

With a banking license in the UK, LHV Bank serves a diverse clientele, including international financial technology companies. The firm is also committed to facilitating loans for small and medium-sized enterprises, in addition to providing essential retail banking services.

Investor Relations and Contact Information

For those seeking further information about LHV Group’s operations or share acquisitions, Sten Hans Jakobsoo is the Head of Investor Relations and Corporate Development. You can reach him at stenhans.jakobsoo@lhv.ee.

Additionally, for communications, Paul Pihlak is the Head of Communications and can be contacted at paul.pihlak@lhv.ee.

Frequently Asked Questions

What is the significance of LHV Group's share acquisition?

The share acquisition reflects LHV Group's commitment to strengthen its market presence and enhance shareholder value.

How many shares did LHV Group acquire during this period?

During the specified period, LHV Group acquired a total of 15,327 shares, affirming their strategic investment approach.

What regulatory compliance is followed during acquisitions?

LHV Group adheres to established guidelines laid out in the general meeting of shareholders and ensures timely disclosures as required by law.

Who can I contact for investor relations at LHV Group?

For investor relations inquiries, you can reach Sten Hans Jakobsoo at his email: stenhans.jakobsoo@lhv.ee.

What are LHV Group's operational pillars?

LHV Group is focused on offering comprehensive financial services, including banking, pensions, and insurance, catering to a diverse clientele.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

FDA Greenlights Kisqali®: A Major Step for Breast Cancer Care

Updated Category News Views 203

Kisqali® Receives FDA Approval for Early Breast Cancer Treatment Novartis has some exciting news for oncology: the US Food and Drug Administration (FDA) has officially approved Kisqali® (ribociclib) as a treatment for patients diagnosed with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) stage II and III early breast cancer...

Continue Reading
Ålandsbanken Abp Launches SEK 350M Additional Tier 1 Notes Series

Updated Category News Views 162

Ålandsbanken Abp Issues SEK 350,000,000 Additional Tier 1 Notes Ålandsbanken Abp, a prominent player in the banking industry, recently made waves in the financial market by issuing Additional Tier 1 floating rate notes amounting to SEK 350,000,000. The issuance marks a significant step in Ålandsbanken's strategic move to strengthen its capital position and enhance its...

Continue Reading
Harbour BioMed's 2025 Achievements and Future Prospects

Updated Category News Views 249

Harbour BioMed Achieves Significant Milestones in Interim Results Harbour BioMed (HKEX: 02142) is a prominent biopharmaceutical company focused on developing innovative antibody therapeutics, particularly in the fields of immunology and oncology. The company shared its impressive interim results for the first half of the year, showcasing remarkable growth and strategic...

Continue Reading
Innovative Investment Fuels Okika Devices' Future Growth Strategy

Updated Category News Views 187

Strategic Investment Boosts Okika Devices Advancement Colorado ONE Fund, which is part of the ONE Funds initiative, has made a major investment in Okika Devices, a company recognized for its innovation in Field Programmable Analog Array (FPAA) technology. This investment aligns with Colorado ONE Fund's mission to support technologies that advance the local innovation...

Continue Reading
Investors Take Note: Legal Options for Shareholders Explored

Updated Category News Views 61

Exploring Legal Options for Investors in Major Companies In recent developments, Halper Sadeh LLC, a reputable law firm focusing on investor rights, is carefully examining three significant companies for potential violations of federal securities laws. This investigation centers around the actions and decisions made by these firms, which may affect shareholders' rights...

Continue Reading